The ongoing Covid-19 pandemic has yielded an unexpected advancement in the pharmaceutical industry with the approval of the first mRNA vaccines, which GlobalData expects will soon impact other indications.
This historical landmark could have significant implications, primarily in the oncology market since mRNA vaccines were being exclusively investigated in infectious and oncology diseases prior to the pandemic. Historically, mRNA vaccines were of interest in the oncology setting because multiple biomarkers could be targeted by this novel mechanism.
Given the current role of immunotherapies in oncology, mRNA vaccines pose a novel approach to trigger immune reactions against cancer cells. However, the novelty of mRNA vaccines has raised regulatory and manufacturing questions in addition to clinical limitations.
Covid-19 approvals showcase potential of mRNA vaccines
The recent approvals of Pfizer / BioNTech’s and Moderna’s mRNA vaccines in healthy patients, complemented by the historically unmatched magnitude to reach healthy patients worldwide, has helped surpass many barriers for mRNA vaccines while highlighting this novel mechanism of action. GlobalData expects this will propagate a new epicenter of interest in pursuing this drug class in oncology.
Currently, there are 44 ongoing clinical trials exploring mRNA vaccines, of which 23 are investigating infectious diseases. This includes Covid-19, which accounts for 60% of those clinical trials. Interestingly, only four out of the 44 clinical trials have made it to Phase III as a result of the sudden and immense demand to prevent the spread of Covid-19.
From an oncology viewpoint, the current pandemic will still serve to provide essential real-world data about the tolerability and effects of mRNA vaccines, since despite their approval and initial vaccination rollout, the long-term efficacy and side effects are still to be understood. As more data are gathered on these vaccines, GlobalData expects an increasing interest in bringing them into the oncology sector.
Key opinion leaders (KOLs) interviewed by GlobalData have repeatedly shown interest in novel mechanisms of action, particularly in immunotherapy. Prior to the pandemic, mRNA vaccines were one of many promising drug classes that were being explored equally with each other, with no expectation about which would be the next to impact the market. However, the sudden rise of mRNA vaccines makes it a prime candidate since there is a current spotlight on this drug class.
A supporting argument for the interest in mRNA vaccines is that out of the 21 ongoing non-infectious disease clinical trials that are exploring mRNA vaccines, all are being developed for oncology indications. Of these 21 trials, only seven are in Phase II, which demonstrates the relatively early stage of mRNA vaccines in oncology. Interestingly, the most represented company in these clinical trials is BioNTech, with seven of the 21 trials, followed by Roche/Genentech with three clinical trials and Moderna Inc with two clinical trials.
Image Credit: Shutterstock
Post by Amanda Scott, NA CEO. Follow her on twitter @tantriclens
Thanks to Heinz V. Hoenen. Follow him on twitter: @HeinzVHoenen
News
Tiny Metal Nanodots Obliterate Cancer Cells While Largely Sparing Healthy Tissue
Scientists have developed tiny metal-oxide particles that push cancer cells past their stress limits while sparing healthy tissue. An international team led by RMIT University has developed tiny particles called nanodots, crafted from a metallic compound, [...]
Gold Nanoclusters Could Supercharge Quantum Computers
Researchers found that gold “super atoms” can behave like the atoms in top-tier quantum systems—only far easier to scale. These tiny clusters can be customized at the molecular level, offering a powerful, tunable foundation [...]
A single shot of HPV vaccine may be enough to fight cervical cancer, study finds
WASHINGTON -- A single HPV vaccination appears just as effective as two doses at preventing the viral infection that causes cervical cancer, researchers reported Wednesday. HPV, or human papillomavirus, is very common and spread [...]
New technique overcomes technological barrier in 3D brain imaging
Scientists at the Swiss Light Source SLS have succeeded in mapping a piece of brain tissue in 3D at unprecedented resolution using X-rays, non-destructively. The breakthrough overcomes a long-standing technological barrier that had limited [...]
Scientists Uncover Hidden Blood Pattern in Long COVID
Researchers found persistent microclot and NET structures in Long COVID blood that may explain long-lasting symptoms. Researchers examining Long COVID have identified a structural connection between circulating microclots and neutrophil extracellular traps (NETs). The [...]
This Cellular Trick Helps Cancer Spread, but Could Also Stop It
Groups of normal cbiells can sense far into their surroundings, helping explain cancer cell migration. Understanding this ability could lead to new ways to limit tumor spread. The tale of the princess and the [...]
New mRNA therapy targets drug-resistant pneumonia
Bacteria that multiply on surfaces are a major headache in health care when they gain a foothold on, for example, implants or in catheters. Researchers at Chalmers University of Technology in Sweden have found [...]
Current Heart Health Guidelines Are Failing To Catch a Deadly Genetic Killer
New research reveals that standard screening misses most people with a common inherited cholesterol disorder. A Mayo Clinic study reports that current genetic screening guidelines overlook most people who have familial hypercholesterolemia, an inherited disorder that [...]
Scientists Identify the Evolutionary “Purpose” of Consciousness
Summary: Researchers at Ruhr University Bochum explore why consciousness evolved and why different species developed it in distinct ways. By comparing humans with birds, they show that complex awareness may arise through different neural architectures yet [...]
Novel mRNA therapy curbs antibiotic-resistant infections in preclinical lung models
Researchers at the Icahn School of Medicine at Mount Sinai and collaborators have reported early success with a novel mRNA-based therapy designed to combat antibiotic-resistant bacteria. The findings, published in Nature Biotechnology, show that in [...]
New skin-permeable polymer delivers insulin without needles
A breakthrough zwitterionic polymer slips through the skin’s toughest barriers, carrying insulin deep into tissue and normalizing blood sugar, offering patients a painless alternative to daily injections. A recent study published in the journal Nature examines [...]
Multifunctional Nanogels: A Breakthrough in Antibacterial Strategies
Antibiotic resistance is a growing concern - from human health to crop survival. A new study successfully uses nanogels to target and almost entirely inhibit the bacteria P. Aeruginosa. Recently published in Angewandte Chemie, the study [...]
Nanoflowers rejuvenate old and damaged human cells by replacing their mitochondria
Biomedical researchers at Texas A&M University may have discovered a way to stop or even reverse the decline of cellular energy production—a finding that could have revolutionary effects across medicine. Dr. Akhilesh K. Gaharwar [...]
The Stunning New Push to Protect the Invisible 99% of Life
Scientists worldwide have joined forces to build the first-ever roadmap for conserving Earth’s vast invisible majority—microbes. Their new IUCN Specialist Group reframes conservation by elevating microbial life to the same urgency as plants and [...]
Scientists Find a Way to Help the Brain Clear Alzheimer’s Plaques Naturally
Scientists have discovered that the brain may have a built-in way to fight Alzheimer’s. By activating a protein called Sox9, researchers were able to switch on star-shaped brain cells known as astrocytes and turn them into [...]
Vision can be rebooted in adults with amblyopia, study suggests
Temporarily anesthetizing the retina briefly reverts the activity of the visual system to that observed in early development and enables growth of responses to the amblyopic eye, new research shows. In the common vision [...]
